Zura Bio
Kate Lindsell, PhD, has an extensive career history in project and portfolio management within the pharmaceutical and biotech industry. She currently holds the position of Head of Portfolio Management at Zura Bio Limited and previously served as Executive Director of Operations Management at Syneos Health. Kate has also held leadership roles at companies such as hVIVO, Retroscreen Virology, and OptumInsight. With a PhD in Virology from UCL and a BSc in Applied Biology from the University of Wales, Cardiff, Kate brings a wealth of expertise to her current role.
This person is not in any offices
Zura Bio
1 followers
Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168 with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders. Zura Bio is headquartered in Henderson, NV with team members in the UK and USA.